FDA panel rejects Emideltide for compounding

United States: The US Food and Drug Administration (FDA) did not include Emideltide (Delta-Sleep-Inducing-Peptide, DSIP) in the 503A bulk substances list on July 24, 2026, after the advisory committee PCAC voted against it with 6 to 7 votes and one abstention. The neuropeptide thus remains prohibited for regulated US compounding pharmacies and remains in a regulatory gray area. When purchasing corresponding DSIP preparations, special caution is advised due to unclear quality and purity standards.

Key facts about the FDA decision on Emideltide (DSIP)

• The FDA PCAC rejected Emideltide (DSIP) for the 503A compounding list on July 24, 2026, with 6:7 votes and one abstention.
• The FDA reviewed Emideltide for chronic insomnia, opioid withdrawal, and narcolepsy, but excluded hypothalamic obesity.
• The FDA considered the efficacy and safety data for subcutaneous injection to be insufficient.
• Six alternative peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) received a positive recommendation from the committee.
• For buyers, Emideltide remains on the gray market; special caution is advised with dealers who falsely advertise the substance as approved.

What is Emideltide (DSIP)?

Emideltide (Delta-Sleep-Inducing-Peptide, DSIP) is a neuropeptide consisting of nine amino acids, originally researched for sleep induction. In the regulatory evaluation process, the FDA reviewed the substance for the indications chronic insomnia, opioid withdrawal, and narcolepsy, but excluded hypothalamic obesity. According to FDA documents (2026)^[1], the scientific evaluation referred to a product for subcutaneous administration with a concentration of 1000 mcg/mL.

Why was Emideltide rejected by the FDA?

The FDA rejected Emideltide because the submitted data on efficacy and safety for subcutaneous administration were insufficient. In the meeting of July 23-24, 2026, the PCAC voted 6 to 7 with one abstention against inclusion in the 503A bulk list. While Emideltide failed to meet the required criteria, according to Newtropin (2026)^[5], six alternative peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) received a positive recommendation.

What does the FDA decision mean for you?

The decision means an increased gray market risk for you, as regulated compounding pharmacies in the US are still not allowed to legally produce Emideltide. Unapproved sources often have unclear purity and quality standards. Before a purchase, you should compare offers against the Vendor Radar warning list and only consider batches with verified certificates of analysis (CoAs).

What happens next in the FDA process?

The final decision will be made by the FDA in the further course of the process, with the PCAC vote serving as a decisive but non-binding basis. Until the final regulatory determination, Emideltide remains in a regulatory gray area. For practical handling and reliable safety standards, structured guides on reconstitution and storage offer well-founded assistance.

No medical advice: This article is for informational purposes only and does not replace medical consultation.